Compare GSK plc (GSK) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Value Index Fund ETF — how do they compare? GSK plc trades at $52.7 (market cap $101.34B), while Vanguard Value Index Fund ETF trades at $218.22. The key difference: GSK plc pays a 3.49% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | VTV | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $220.51 |
52-Week Low | $36.20 | $175.51 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
VTV trades at $218.33, down slightly by 0.13% on the day, with a bearish technical signal but bullish moving averages. The ETF has gained 16% year-to-date and 27% over the past year, driven by investor rotation away from tech into value stocks. Recent news highlights its role as a defensive play amid AI bubble concerns and potential Fed rate hikes, with a focus on large-cap value exposure and a low 0.03% expense ratio.
Outlook remains positive for value-oriented investors seeking diversification from tech concentration, supported by strong inflows and media optimism. Key risks include inflation sensitivity and Fed policy shifts, but the ETF's low-cost structure and dividend yield provide stability. Analyst sentiment is favorable given current market dynamics favoring value stocks over growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
